All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.
Health Discovery Corporation (OTCBB: HDVY), the molecular diagnostics company that launched the first SVM-based image analysis iPhone app for melanoma risk assessment, MelApp, today debuts MelApp 2.0 for iPhone. This updated version introduces a new Quiz feature that better educates users on melanoma cases with sample histories and provides the ability to practice assessing the risk factor from a collection of chronicled case photos. New functionality improvements include the capability of drawing the outline of their mole or freckle to better define its location within the captured images. “In developing this new version, our focus was on better functionality, but above all, educating users on the dangers of melanoma, signs, symptoms, and how to check your skin most effectively,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “Health Discovery Corporation’s scientific expertise lies in the development of clinical tests and medical screenings; and the development and improvement of the MelApp mobile app is an extension of using our advanced mathematical techniques to potentially save lives.” Now available for iPhone, iPod touch, iPad, and Android, MelApp is available for download at the iTunes App Store and Android Marketplace at a special price of $1.99. MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze an uploaded image. The app was validated using an image database licensed from Johns Hopkins University Medical Center and uses a device’s camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. In addition, MelApp can use a smartphone’s GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical attention. Physicians who diagnose and treat melanoma can become a subscribing member of HDC’s physician referral network by contacting email@example.com. For support and technical inquiries, contact firstname.lastname@example.org. MelApp by Health Discovery Corporation is available at a special limited time introductory price of $1.99. For more complete details, visit http://www.melapp.net, http://www.facebook.com/MelApp or http://twitter.com/#!/SafeHealthApps. About Health Discovery Corporation Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.